US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
VAUGHAN, Ontario - Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company with annual revenues of $4.8 billion and impressive 12% year-over-year growth, has announced the U.S. launch of two new eye care products, Blink Nourish and Blink Boost, expanding its Blink range of eye drops. The products are now available at major national retailers across the United States, including Walmart, Target, CVS, Walgreens, and Amazon.
Blink Nourish is notable for being the first vitamin-enriched, preservative-free eye drop on the market, specifically designed to replenish and rebalance the tear film. Its unique formula delivers essential nutrients such as vitamin B12, vitamin C, magnesium, and amino acids directly to the eye’s surface. Additionally, the drops contain glycerin for hydration, hyaluronan (HA), and trehalose to promote tear film stability.
On the other hand, Blink Boost is designed with a pH-balanced formula that mimics healthy tears for comfortable application. It contains HA, an electrolyte, and an antioxidant to protect HA from free radicals, all inspired by the Tear Film and Ocular Surface Society’s DEWS II report.
John Ferris, president of Consumer at Bausch + Lomb, emphasized that both Blink Nourish and Blink Boost provide long-lasting relief and are suitable for individuals with sensitive eyes. Optometrist Gina Wesley from Complete Eye Care in Medina, Minnesota, highlighted that the new preservative-free options are beneficial for patients with dry eye symptoms and sensitivities.
The manufacturer’s suggested retail price for Blink Nourish is $15.99 for a 10mL bottle, and Blink Boost is priced at $13.99 for the same volume.
Bausch + Lomb, headquartered in Vaughan, Ontario, and with corporate offices in Bridgewater, New Jersey, has a comprehensive portfolio of approximately 400 products. The company has a significant global presence, with approximately 13,500 employees and operations in around 100 countries. With a market capitalization of $4.06 billion and a strong gross profit margin of 60%, the company maintains a FAIR financial health score according to InvestingPro analysis, which offers comprehensive insights through its Pro Research Report covering 1,400+ top US stocks.
The information for this article is based on a press release statement. For more details on the Blink family of products, visit www.justblink.com. Currently trading at $11.50, with analysts setting price targets ranging from $11 to $19, investors can access detailed financial analysis and additional ProTips through InvestingPro, which provides exclusive insights into the company’s valuation and growth prospects.
In other recent news, Bausch & Lomb Corporation reported its first-quarter financial results, revealing a revenue of $1.137 billion, which represents a 3.5% increase year-over-year but fell short of the anticipated $1.150 billion. The company experienced a net loss of $212 million, significantly higher than the estimated $59 million loss. The revenue was adversely affected by a voluntary recall of enVista lenses, costing approximately $55 million. Despite these challenges, Bausch & Lomb raised its full-year revenue guidance to $5.0-$5.1 billion, expressing confidence in future performance.
Additionally, Bausch & Lomb introduced Zenlens CHROMA HOA scleral contact lenses in the United States, designed to correct higher-order aberrations and improve visual clarity. In other corporate developments, shareholders at the company’s annual meeting elected ten directors and approved executive compensation, with PricewaterhouseCoopers LLP appointed as the auditor until 2026. Analyst Yi Chen from H.C. Wainwright adjusted the company’s stock price target to $15, down from $20, while maintaining a Buy rating, citing uncertainties around tariffs. These recent developments reflect Bausch & Lomb’s ongoing efforts to navigate market challenges and expand its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.